NEVVI Medicare utilization intelligence
Compare this code with others

Jump to the result views

J3245 Injection, tildrakizumab, 1 mg HCPCS · Treatment
Classification Treatment › Injections and Infusions (nononcologic) › Injection - Monoclonal Antibodies (CMS RBCS)
First observed 2019
National scale 2.55M services · est. ▲ 28.3% YoY · 5,255 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1.28M observed fee-for-service services
CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window · National figures — the SC market is below
Data year CY2024 CY2023 CY2022 locked column CY2021 locked column CY2020 locked column
Filter results:
Market summary
Market Brief J3245
A shareable PDF report summarizing this market’s size, trends, and providers.
Preview this Brief →

This market's Overview — its estimated all-Medicare volume, national benchmarks, and what the field charges and is paid — is part of Explore.

See what Medicare pays

An Explore subscription, $249 a seat a year, opens the Overview on every code, group and clinician page, including what the market charges and is paid.

It comes with 25 credits a seat a year for Deep Dives, which open the rest.

Subscribe to Explore →

Included in Explore. Part of a Deep Dive.
Continue from here